Literature DB >> 22532639

Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis.

Féline Kroon1, Robert Landewé, Maxime Dougados, Désirée van der Heijde.   

Abstract

OBJECTIVES: The aim was to compare continuous and on-demand NSAID treatment with respect to their ability to suppress radiographic progression in subgroups of patients with high/elevated CRP-levels, ESR, ASDAS-levels or BASDAI-levels in comparison to patients with normal levels.
METHODS: Post-hoc analyses were performed in a randomized trial comparing continuous and on-demand NSAID treatment. Relevant high/elevated subgroups were created based on time-averaged (ta) CRP (>5mg/L), ta-ESR (>12mm/hr), ta-BASDAI (>4), ta-ASDAS-CRP (>2.1) and ta-ASDAS-ESR (>2.1). Subgroups were further split according to NSAID-use (continuous vs. on-demand). Radiological progression was presented in probability plots. Statistical interactions were tested using multiple and logistic regression analysis. Differences in radiological progression were analysed using the Chi-square and Mann-Whitney U test.
RESULTS: 150 participants randomized to either the continuous-treatment group (n=76), or the on-demand group (n=74) had complete radiographs and were included. The effect of slowing radiological progression with continuous NSAID therapy was more pronounced in patients with elevated ta-CRP-levels, elevated ta-ESR, high ta-ASDAS-CRP or high ta-ASDAS-ESR versus patients with low/normal values. No such effect was found for participants with high vs. low BASDAI. Also, in participants with elevated ta-ESR (irrespective of treatment), there appeared to be a higher rate of structural progression than in participants with normal ta-ESR. Regression analyses showed that continuous NSAID treatment neutralizes the negative effect of inflammation (high ta-ESR).
CONCLUSIONS: Patients with elevated acute phase reactants seem to benefit most from continuous treatment with NSAIDs. Continuous NSAID-therapy in patients with elevated acute phase reactants may lead to an improved benefit-risk-ratio of these drugs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22532639     DOI: 10.1136/annrheumdis-2012-201370

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  62 in total

Review 1.  Review: Enthesitis: New Insights Into Pathogenesis, Diagnostic Modalities, and Treatment.

Authors:  Amy S Kehl; Maripat Corr; Michael H Weisman
Journal:  Arthritis Rheumatol       Date:  2016-02       Impact factor: 10.995

Review 2.  Structural Disease Progression in Axial Spondyloarthritis: Still a Cause for Concern?

Authors:  Barbara Neerinckx; Rik J Lories
Journal:  Curr Rheumatol Rep       Date:  2017-03       Impact factor: 4.592

Review 3.  Advances and challenges in spondyloarthritis imaging for diagnosis and assessment of disease.

Authors:  Ulrich Weber; Walter P Maksymowych
Journal:  Curr Rheumatol Rep       Date:  2013-08       Impact factor: 4.592

Review 4.  Therapies of Early, Advanced, and Late Onset Forms of Axial Spondyloarthritis, and the Need for Treat to Target Strategies.

Authors:  Nurullah Akkoc; Gercek Can; Salvatore D'Angelo; Angela Padula; Ignazio Olivieri
Journal:  Curr Rheumatol Rep       Date:  2017-02       Impact factor: 4.592

Review 5.  Ankylosis in ankylosing spondylitis: current concepts.

Authors:  Nigil Haroon
Journal:  Clin Rheumatol       Date:  2015-06       Impact factor: 2.980

Review 6.  Radiographic Progression in Ankylosing Spondylitis: From Prognostication to Disease Modification.

Authors:  Ismail Sari; Nigil Haroon
Journal:  Curr Rheumatol Rep       Date:  2018-11-08       Impact factor: 4.592

Review 7.  New evidence on the management of spondyloarthritis.

Authors:  Joachim Sieper; Denis Poddubnyy
Journal:  Nat Rev Rheumatol       Date:  2016-04-07       Impact factor: 20.543

Review 8.  Syndesmophyte growth in ankylosing spondylitis.

Authors:  Sovira Tan; Runsheng Wang; Michael M Ward
Journal:  Curr Opin Rheumatol       Date:  2015-07       Impact factor: 5.006

9.  Unanswered questions in the management of axial spondyloarthritis: an opinion piece.

Authors:  Xenofon Baraliakos; Atul Deodhar
Journal:  Clin Rheumatol       Date:  2014       Impact factor: 2.980

10.  Multimonth controlled small molecule release from biodegradable thin films.

Authors:  Bryan B Hsu; Myoung-Hwan Park; Samantha R Hagerman; Paula T Hammond
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.